Company Overview
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +85.68% |
| 6 Months: | -21.20% |
| 3 Months: | +50.99% |
| 1 Month: | -8.47% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)47.41 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 29.4% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MSLE Satellos Bioscience Inc. PHARMA | 9.18 | -4.71 | $194.77M | 0.00% | -95.23% | -70.45% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 6.48M | 6.37M | 5.97M | 7.65M | 10.04M |
| Operating Income | - | -6.48M | -6.37M | -5.97M | -7.65M | -10.04M |
| EBITDA | - | -6.48M | -6.37M | -5.96M | -7.65M | -10.04M |
| Interest Expense | 0 | - | - | - | - | - |
| Pretax Income | - | -6.08M | -5.58M | -5.80M | -7.25M | -9.73M |
| Tax Provision | - | 63.00K | 32.00K | 19.00K | 58.00K | 33.00K |
| Net Income | - | -6.14M | -5.61M | -5.82M | -7.30M | -9.77M |
| Diluted EPS | - | -0.44 | -0.36 | -0.36 | - | -0.53 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | 94.05K | - | - | - | - |
| Gross Profit | -94.05K | - | - | - | - |
| Operating Expenses | - | 6.21M | 11.66M | 20.40M | 26.46M |
| Operating Income | - | -6.21M | -11.66M | -20.40M | -26.46M |
| EBITDA | - | -8.09M | -11.84M | -20.38M | -26.45M |
| Interest Expense | 772.80K | 0 | 133.42K | 0 | - |
| Pretax Income | - | -8.34M | -11.98M | -20.63M | -24.70M |
| Tax Provision | - | 3.68K | 0 | 0 | 172.00K |
| Net Income | - | -8.34M | -11.98M | -20.63M | -24.87M |
| Diluted EPS | - | -2.83 | -1.63 | -2.16 | -1.70 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 4.57M | 33.49M | 50.75M | 31.89M |
| Current Assets | - | 1.65M | 30.48M | 50.74M | 31.88M |
| Cash & Equivalents | - | 1.42M | 16.68M | 40.07M | 9.80M |
| Inventory | - | - | - | - | - |
| Receivables | 1.40K | 0 | - | - | - |
| Total Liabilities | - | 2.09M | 2.73M | 3.58M | 4.11M |
| Current Liabilities | - | 2.09M | 2.73M | 3.58M | 4.11M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | - | - | - | - |
| Total Equity | - | 2.48M | 30.76M | 47.16M | 27.78M |
| Shares Outstanding | - | 3.48M | 9.40M | 13.82M | 15.46M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -4.26M | -8.73M | -18.25M | -23.60M |
| Investing Cash Flow | - | -2.21K | -13.22M | 4.66M | -9.42M |
| Financing Cash Flow | - | 2.04M | 38.01M | 37.57M | 2.24M |
| Capital Expenditure | - | -2.21K | -13.57K | -4.00K | -6.00K |
| Free Cash Flow | - | -4.26M | -8.75M | -18.26M | -23.60M |
| Net Change in Cash | - | -2.12M | 16.06M | 23.98M | -30.77M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -336.1% | -38.9% | -43.7% | -89.5% |
| ROCE % | - | -250.2% | -37.9% | -43.2% | -95.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Franklin Resources, Inc. | 4.42% | 938.67K | $8.75M |
| 2 | Siren, L.L.C. | 4.20% | 892.07K | $8.31M |
| 3 | Vivo Capital, LLC | 3.84% | 813.67K | $7.58M |
| 4 | Point72 Asset Management, L.P. | 3.22% | 682.70K | $6.36M |
| 5 | Sphera Funds Management Ltd. | 3.08% | 652.59K | $6.08M |
| 6 | Woodline Partners LP | 2.36% | 500.43K | $4.66M |
| 7 | Stonepine Capital Management, LLC | 2.32% | 491.62K | $4.58M |
| 8 | Montanova Capital LLC | 2.24% | 475.00K | $4.43M |
| 9 | Avidity Partners Management, LP | 1.83% | 387.77K | $3.61M |
| 10 | Saturn V Capital Management LP | 1.65% | 350.00K | $3.26M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MSLE
Satellos to Participate in Upcoming Investor Conferences - Stock Titan
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNVDBhTEVMY1YwQUE0TU5NdG5VLUR0bS1IVlROTU9jLW9NY2RpWDl0bzhEa2hTYjktQnJWS0EybGVRamR0b1NnU3Z4dE1XQVlrNmljVzduQWdLU3dZRmxySl9jSmRDcUl0RkEwcU1OTjJWbTVpcXIxY0c5VXRXM3lGMm5yNTFDYlVCMmVQU2…
Satellos Bioscience Inc. (NASDAQ:MSLE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxOT1VBZ0tlQ1RabDludlhVeThXZnNESzBiWTE2OEZWejlnS3JLMGRpZUZuYWVuSTdQLVQ0aHZmTVZuVmNWdTh0ekFmV01meXlxMUU0aFBYZXpjMTVoMXp5X2JGVU5IUGEyS2g0aEZfWVlOa2NNM2hwYnlYTjRNdTdrTVd3RmpBRFBGbk4xeG…
Why MSLE Stock Gave Up All Nasdaq Debut Gains And Fell 8% After Hours - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxOMVFGZzdxRXFyQXpFT05XYklDWlE3YnJiR0s2WGJqaTVTczR6MUdiZlUzSHBRbC14dGNKTUlVUlRHMW5OSzBZRmxwMi1PbWU4TllXYUtSXzFnOXRCbkNlRnQ0OVFaM2tTTlpBaUY3dDQtN1RjNzlmTkpRWUU5cFN4ZXRPU2NGelJKMUVCdE…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFBhVUxOVHJrXy02ejR5djNsTmF2V1A4eEJNMXVoamp0cUI3WDVvVEFueEtUT0ZEUlFGRVJQbU9iSm15VEVybEllWWRvVlJYX1VX?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
Satellos Bioscience: Q2 Earnings Snapshot - ktvb.com
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxNNDRfeGdVQnpLZWNQa2YyelhaUDJ4ZjVEN1huNmlvQnpXbFRTZXF0am81cF9CUDZyc0UzakFTclRUSFptcFU1V2ZBbVR2Zkd1dWFTODlBNVY3TEFtaUh4djlraDlTRzVHek1mX19KeVVyVmtYcTJXNXVnSXZISGJjeW5Db29JcFpKYTRFaG…
Satellos Bioscience Inc. - Common Stock (MSLE) Stock Price, News, Quote & History - FinancialContent
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTFA4QzBtQTc3Wk8yVVdfSXBUSC1NWkRmak5oMTEtV1lqWi1HYnk3bXBFUVB4UVZRcmYxS2ZQM05udEVIU2xmRU9zbnF3NVJUWUMzQWJkdU9NdmdkZw?oc=5" target="_blank">Satellos Bioscience Inc. - Common Stock (MSLE…
MSLE — Frequently Asked Questions
What is the current share price of Satellos Bioscience Inc. (MSLE)?
As of 2026-09-19 21:16 PDT, Satellos Bioscience Inc. (MSLE) trades at $9.18 on NasdaqGM. Its 52-week range is $4.85 to $13.01.
What is the market capitalisation of MSLE?
Satellos Bioscience Inc. (MSLE) has a market capitalisation of $194.77M on NasdaqGM.
What is the P/E ratio of MSLE?
MSLE trades at a trailing price-to-earnings (P/E) ratio of -4.71. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.24.
What is the return on equity (ROE) of MSLE?
MSLE has a return on equity (ROE) of -70.45%. Its return on capital employed (ROCE) is -95.23%.
Is MSLE a good stock to buy?
This page provides a data-driven analysis of Satellos Bioscience Inc. (MSLE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.